Metabolic & Weight Research
Research on GLP compounds and peptides for metabolic regulation, body composition, and fat loss. Phase 2 Retatrutide data, STEP trial semaglutide data, and SURMOUNT tirzepatide data.
Metabolic & Weight Loss Research
GLP receptor agonist compounds have produced the most significant advances in fat loss research in decades. The data across three generations of compounds shows progressive improvement with each additional receptor engagement.
Clinical Trial Summary
| Compound | Trial | Duration | Mean Weight Loss |
| Semaglutide 2.4mg | STEP 1 | 68 weeks | −14.9% |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | −20.9% |
| Retatrutide 8mg | Phase 2 | 48 weeks | −28.7% |
Triple-Agonist Mechanism of Weight Loss
Retatrutide's superior weight loss derives from three concurrent mechanisms:
1. GLP-1R activation: Hypothalamic appetite suppression, slowed gastric emptying, extended satiety 2. GIPR activation: Enhanced insulin sensitivity, adipocyte lipid metabolism effects 3. GcgR activation: Hepatic fat oxidation, brown adipose thermogenesis — fat burning independent of appetite reduction
Visceral Fat Targeting
GLP compounds preferentially reduce visceral adipose tissue — the metabolically active, inflammatory fat depot associated with cardiometabolic risk. Retatrutide's glucagon receptor engagement drives preferential visceral fat mobilization through enhanced lipolysis in this depot specifically.
The Clavicular Stack Weight Loss Protocol
The Clavicular Stack uses Retatrutide (GLP-3 R) as the core fat loss compound with an escalating dose protocol:
- Week 1-4: 2mg/week
- Week 5-8: 4mg/week
- Week 9+: 8mg/week (Phase 2 optimal dose)
Research-Grade Metabolic & Weight Research
>98% purity, third-party tested. Free shipping on orders over $200.
Metabolic & Weight Research — Available Products
Research-grade compounds from Clavicular Stack. >98% purity, CoA on request.
GLP-3 R 15mg
Retatrutide (GLP-3 R) 15mg — the standard research supply for triple agonist studies. Enables full head-to-head protocols: GLP-1 monotherapy (semaglutide) vs. dual agonism (tirzepatide) vs. triple agonism (retatrutide) in matched in vitro or animal models.
CAS: 2381609-35-2
GLP-3 R 60mg
GLP-3 R (Retatrutide) 60mg — the bulk research vial for extended Retatrutide studies. Triple-agonist GLP-1/GIP/Glucagon receptor activity. Phase 2 trial data shows −28.7% body weight reduction at 48 weeks.
CAS: 2381609-35-2
GLP-2 T 15mg
Tirzepatide (GLP-2 T) is a dual GLP-1/GIP receptor agonist — activating both incretin receptors simultaneously for additive effects on insulin secretion and energy intake reduction. Research shows significantly greater weight reduction in obese models vs. GLP-1 monotherapy. Frequently compared head-to-head with semaglutide in mechanistic studies. 15mg lyophilized, >98% purity.
CAS: 2023788-19-2
Research Guides
Deep-dive guides for metabolic & weight research compounds
Guide
Retatrutide (GLP-3 R): Complete Research Guide
Everything researchers need to know about Retatrutide — the triple-agonist GLP-1/GIP/Glucagon compound at the core of the Clavicular Stack. Phase 2 data, mechanism, dosing, and sourcing.
Read guideGuide
Peptide Reconstitution Guide: BAC Water, Storage & Handling
Step-by-step guide to reconstituting lyophilized research peptides — bacteriostatic water ratios, injection technique, storage conditions, and quality control for all Clavicular Stack compounds.
Read guideGuide
Retatrutide vs. Semaglutide vs. Tirzepatide: GLP Research Comparison
A side-by-side comparison of the three main GLP compounds — GLP-1 only (semaglutide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/Glucagon (Retatrutide). Data, mechanisms, and why Clav chose GLP-3 R.
Read guideRelated Research
Articles and breakdowns for metabolic & weight research
10 min read
Clavicular's Peptide Stack: Full Breakdown of the Clav Protocol
The complete breakdown of Clavicular's viral looksmaxxing peptide protocol — what each compound does, why Clav chose it, exact doses, and where to source the stack.
Read more8 min read
Why BPC-157 Is Essential When Running GLP Peptides
The research rationale for pairing BPC-157 with Retatrutide and other GLP compounds — gastric cytoprotection, nausea reduction, and gut barrier integrity during GLP protocol research.
Read more11 min read
Looksmaxxing Peptides 2026: The Complete Research Guide
The complete guide to research peptides for looksmaxxing in 2026 — fat loss (GLP-3 R), skin (GHK-CU), recovery (BPC-157), hair, and more. How each compound addresses a specific looksmax target.
Read moreLooking for Clavicular's Looksmaxxing Stack?
See which peptides Clavicular uses in his viral looksmaxxing transformation — Retatrutide, BPC-157, and more.
Frequently Asked Questions
What weight loss can Retatrutide achieve?
Phase 2 trial data (48 weeks, 8mg/week) showed -28.7% mean body weight reduction — the largest result ever recorded in a Phase 2 GLP compound trial. Weight loss trajectory had not plateaued at 48 weeks.
How does the Clavicular Stack optimize fat loss?
The stack uses Retatrutide (GLP-3 R) as the triple-agonist core for fat loss, BPC-157 to protect GI function during GLP dose escalation, and GHK-CU to optimize skin quality as fat reduces.
Which compound is better for fat loss research?
Phase 2 data supports Retatrutide > tirzepatide > semaglutide in terms of magnitude of effect (-28.7% vs -20.9% vs -14.9%), driven by each compound's additional receptor engagement.
Shop Metabolic & Weight Research
Research-grade metabolic & weight research from Clavicular Stack. Third-party tested, >98% purity guaranteed.